國開國際投資(01062.HK)擬掛牌出售北京遠東25%股權
格隆匯9月24日丨國開國際投資(01062.HK)發佈公告,公司全資附屬公司亞太投資於2020年9月24日在北京產權交易所有限公司以掛牌轉讓方式建議出售其於北京遠東的25%股權。建議出售事項的交易底價為人民幣8132萬元。
北京遠東為中國領先的工業精密儀表製造商,其主要業務為製造儀表及精準量度儀器。公司於北京遠東的投資根據香港會計準則第28號(修訂本)於聯營公司及合營企業的投資入賬。
董事會認為,建議出售事項與公司達致其資產中線及長線的資本增值的目標一致。倘建議出售事項落實,則會自建議出售事項實現資本增值,這將對公司財務狀況有正面影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.